MEDICLIN Reports Strong Nine-Month Performance with Significant Profit Growth

MEDICLIN Aktiengesellschaft generated consolidated group sales of €586.9 million in the first nine months of 2025, representing a 5.1% increase compared to the same period last year. The group operating result showed substantial improvement, reaching €48.9 million compared to €34.5 million in the first nine months of 2024. Overall capacity utilisation within the Group remained stable at 86.8%, slightly above the previous year's level of 86.0%.

The post-acute segment delivered particularly strong results, with sales increasing by 9.3% to €394.6 million. Segment operating result in this division rose by €9.6 million to €47.6 million, while the cost of materials ratio improved by 0.9 percentage points to 19.5%. Personnel expenses in the post-acute segment increased by 9.4% to €205.0 million, primarily due to salary increases and higher employee numbers, though the personnel expense ratio remained unchanged at 51.9%.

Developments in the acute segment were significantly influenced by the sale of the former MEDICLIN Herzzentrum Coswig, resulting in a 3.2% decrease in segment sales. Despite this reduction, the segment's operating result improved dramatically by €4.5 million to €0.7 million, reversing a loss position from the previous year. The cost of materials in the acute segment fell by 4.8% to €47.6 million, while personnel expenses decreased by 4.8% to €101.0 million. The interim report as of 30 September 2025 is available in German and English at https://www.mediclin.de.

In the nursing care segment, sales amounted to €18.6 million, though the segment operating result declined to a loss of €0.4 million. The service segment showed positive development with sales increasing to €74.8 million and segment operating result improving by €0.8 million to €1.0 million. The Management Board confirmed its guidance for the 2025 financial year, expecting consolidated group sales growth between 2.0% and 5.0% and consolidated group EBIT between €53.0 million and €64.0 million.

Tino Fritz, CFO of MEDICLIN, commented that in view of current conditions and typical seasonal effects in the fourth quarter, the company continues to assess business development as solid. The current quarterly results demonstrate that MEDICLIN will achieve its original annual guidance and successfully conclude the current financial year. The original release can be viewed on https://www.newmediawire.com.